OpenBilldrug price receipt

NADAC week of 2026-10-14

HADLIMA 40 MG/0.8 ML SYRINGE

FDA nonproprietary name: adalimumab-bwwd

For 1.6 mL

Pharmacies pay

$987.43 filed

1.6 × $617.14196 per ML

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$1,003.14 filed

1.6 × $626.9605 per ML, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.0× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Hadlima” / “Adalimumab-Bwwd” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$1,140.54 estimated

$987.43 + $148.11 (15%) + $5.00 fee per fill = $1,140.54

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

HADLIMA 40 MG/0.8 ML SYRINGE is how the CMS NADAC file names this product. The FDA NDC Directory lists it as adalimumab-bwwd, under the trade name “Hadlima”.

FDA gives its dosage form as solution and its route as subcutaneous.

The labeler, the company named on the label, is Organon LLC.

FDA’s Established Pharmacologic Class for it is Tumor Necrosis Factor Blocker.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 78206-0183-01.

NADAC classes it in its brand rate-setting class B-BIO, and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $987.43 for 1.6 mL (1.6 × $617.14196 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

The NDC

Other strengths, forms and brands

3 other products in the NADAC file share the FDA nonproprietary name adalimumab-bwwd with HADLIMA 40 MG/0.8 ML SYRINGE.

ProductPharmacies pay per unitMedicare per unit
HADLIMA 40 MG/0.8 ML SYRINGE this page
brand · solution
$617.14196 per ML filed
eff. 2026-09-23
$626.9605 per ML filed
Part D 2024 average
HADLIMA PUSHTOUCH 40 MG/0.8 ML
brand · solution
$623.49306 per ML filed
eff. 2026-09-23
We don’t know yet
HADLIMA(CF) 40 MG/0.4 ML SYRINGE
brand · solution
$1,258.37813 per ML filed
eff. 2026-09-23
We don’t know yet
HADLIMA(CF) PUSHTOUCH 40 MG/0.4 ML
brand · solution
$1,259.15439 per ML filed
eff. 2026-09-23
We don’t know yet

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $617.14196 per ML filed.

Of the 10 other products in FDA’s Tumor Necrosis Factor Blocker class priced per ML, 10 have a higher middle NADAC price and 0 a lower one. The one in the middle is ENBREL 50 MG/ML SYRINGE, at $2,080.59222 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $1,003.14 for 1.6 mL, at an average of $626.9605 per ML in 2024 (2024-01-01 to 2024-12-31) for “Hadlima” and “Adalimumab-Bwwd”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 278 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for HADLIMA 40 MG/0.8 ML SYRINGE labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Hadlima / Adalimumab-Bwwd: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
Why does this page start at 1.6 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1.6 mL in one package for this product’s NDC (“2 CARTON in 1 CARTON (78206-183-01) / 1 SYRINGE in 1 CARTON (78206-183-99) / .8 mL in 1 SYRINGE”), so the card starts at one package: 1.6 ML. Change it to match your prescription.